Skip to main content
Journal cover image

Renal function and coronary bypass surgery in patients with ischemic heart failure.

Publication ,  Journal Article
Doenst, T; Haddad, H; Stebbins, A; Hill, JA; Velazquez, EJ; Lee, KL; Rouleau, JL; Sopko, G; Farsky, PS; Al-Khalidi, HR ...
Published in: J Thorac Cardiovasc Surg
February 2022

OBJECTIVE: Chronic kidney disease is a known risk factor in cardiovascular disease, but its influence on treatment effect of bypass surgery remains unclear. We assessed the influence of chronic kidney disease on 10-year mortality and cardiovascular outcomes in patients with ischemic heart failure treated with medical therapy (medical treatment) with or without coronary artery bypass grafting. METHODS: We calculated the baseline estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration formula, chronic kidney disease stages 1-5) from 1209 patients randomized to medical treatment or coronary artery bypass grafting in the Surgical Treatment for IsChemic Heart failure trial and assessed its effect on outcome. RESULTS: In the overall Surgical Treatment for IsChemic Heart failure cohort, patients with chronic kidney disease stages 3 to 5 were older than those with stages 1 and 2 (66-71 years vs 54-59 years) and had more comorbidities. Multivariable modeling revealed an inverse association between estimated glomerular filtration rate and risk of death, cardiovascular death, or cardiovascular rehospitalization (all P < .001, but not for stroke, P = .697). Baseline characteristics of the 2 treatment arms were equal for each chronic kidney disease stage. There were significant improvements in death or cardiovascular rehospitalization with coronary artery bypass grafting (stage 1: hazard ratio, 0.71; confidence interval, 0.53-0.96, P = .02; stage 2: hazard ratio, 0.71; confidence interval, 0.59-0.84, P < .0001; stage 3: hazard ratio, 0.76; confidence interval, 0.53-0.96, P = .03). These data were inconclusive in stages 4 and 5 for insufficient patient numbers (N = 28). There was no significant interaction of estimated glomerular filtration rate with the treatment effect of coronary artery bypass grafting (P = .25 for death and P = .54 for death or cardiovascular rehospitalization). CONCLUSIONS: Chronic kidney disease is an independent risk factor for mortality in patients with ischemic heart failure with or without coronary artery bypass grafting. However, mild to moderate chronic kidney disease does not appear to influence long-term treatment effects of coronary artery bypass grafting.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Thorac Cardiovasc Surg

DOI

EISSN

1097-685X

Publication Date

February 2022

Volume

163

Issue

2

Start / End Page

663 / 672.e3

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Respiratory System
  • Renal Insufficiency, Chronic
  • Prospective Studies
  • Myocardial Ischemia
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Doenst, T., Haddad, H., Stebbins, A., Hill, J. A., Velazquez, E. J., Lee, K. L., … Working Group and Surgical Treatment for IsChemic Heart failure Trial Investigators. (2022). Renal function and coronary bypass surgery in patients with ischemic heart failure. J Thorac Cardiovasc Surg, 163(2), 663-672.e3. https://doi.org/10.1016/j.jtcvs.2020.02.136
Doenst, Torsten, Haissam Haddad, Amanda Stebbins, James A. Hill, Eric J. Velazquez, Kerry L. Lee, Jean L. Rouleau, et al. “Renal function and coronary bypass surgery in patients with ischemic heart failure.J Thorac Cardiovasc Surg 163, no. 2 (February 2022): 663-672.e3. https://doi.org/10.1016/j.jtcvs.2020.02.136.
Doenst T, Haddad H, Stebbins A, Hill JA, Velazquez EJ, Lee KL, et al. Renal function and coronary bypass surgery in patients with ischemic heart failure. J Thorac Cardiovasc Surg. 2022 Feb;163(2):663-672.e3.
Doenst, Torsten, et al. “Renal function and coronary bypass surgery in patients with ischemic heart failure.J Thorac Cardiovasc Surg, vol. 163, no. 2, Feb. 2022, pp. 663-672.e3. Pubmed, doi:10.1016/j.jtcvs.2020.02.136.
Doenst T, Haddad H, Stebbins A, Hill JA, Velazquez EJ, Lee KL, Rouleau JL, Sopko G, Farsky PS, Al-Khalidi HR, Working Group and Surgical Treatment for IsChemic Heart failure Trial Investigators. Renal function and coronary bypass surgery in patients with ischemic heart failure. J Thorac Cardiovasc Surg. 2022 Feb;163(2):663-672.e3.
Journal cover image

Published In

J Thorac Cardiovasc Surg

DOI

EISSN

1097-685X

Publication Date

February 2022

Volume

163

Issue

2

Start / End Page

663 / 672.e3

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Respiratory System
  • Renal Insufficiency, Chronic
  • Prospective Studies
  • Myocardial Ischemia
  • Middle Aged
  • Male